格隆汇1月26日丨特宝生物(688278.SH)公布向不特定对象发行可转换公司债券预案，本次发行可转债募 集资金总额（含发行费用）不超过人民币15.33亿元（含本数），扣除发行费用后的募集资金净额将用 于以下项目：新药研发项目、生物技术创新融合中心建设项目、特宝生物创新药物生产改扩项目-产线 建设。 ...

格隆汇1月26日｜据港交所文件，北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

据港交所文件：北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

证券日报网讯1月26日，前沿生物在互动平台回答投资者提问时表示，FB7013作为全球首个申报临床、 靶向补体凝集素途径关键蛋白MASP-2的siRNA药物，具备同类首创(First-in-Class)潜力，临床前数据显 示，在健康食蟹猴中，单次皮下注射后血清MASP-2蛋白最大敲降幅度超95%，药效可持续105天以上， 预期临床阶段有望实现每3-6个月给药一针的便捷频率，可大幅提升患者用药依从性；在食蟹猴IgA肾病 模型中，该药物能剂量依赖性改善尿总蛋白肌酐比值(uPCR)、尿总蛋白(uTP)及肾小球滤过率(eGFR)等 核心指标，高剂量治疗8周后肾小球IgA沉积减少43%，系膜细胞数量下降36%，且脱靶分析显示无明显 脱靶风险，安全性良好。截至2025年末，公司已就FB7013向国家药监局提交IND申请并获受理， FB7013正式进入临床申请审批通道。关于BD合作事宜，公司始终秉持开放的态度，积极探索符合产品 发展战略的合作机会。 ...

Core Viewpoint - Tonghua Dongbao is expected to achieve a significant turnaround in its financial performance for 2025, with a projected net profit of approximately 1.242 billion yuan and a net profit excluding non-recurring gains of about 402 million yuan, both showing a substantial recovery compared to the previous year [1] Group 1: Performance Highlights - The company's insulin analog products are experiencing rapid growth, with sales increasing by over 100% year-on-year, becoming the main driver of revenue growth [2] - In Q3 2025, revenue from insulin analogs surpassed that of traditional human insulin, marking a key milestone in product upgrade [2] - Tonghua Dongbao's market share in the insulin sector remains second in the industry, with human insulin market share rising to 45.5%, maintaining the leading position domestically [2] Group 2: R&D Progress - The company is increasing R&D investment, advancing multiple innovative drug projects in the metabolic disease field [3] - Significant progress has been made with GLP-1 drugs, including the completion of Phase III clinical trials for semaglutide and positive results from Ib phase trials for a GLP-1/GIP dual-target agonist [3] - The company is also accelerating the development of insulin combination formulations and has received marketing approval for a gout drug, showcasing a diversified pipeline [3] Group 3: International Expansion - Tonghua Dongbao's internationalization has accelerated, with several core products achieving registration and market access breakthroughs in emerging markets [4] - The company is implementing a dual-output model of "raw materials + formulations," with significant progress in the internationalization of insulin analogs and human insulin [4] - The strategy includes breakthroughs in mature markets and rapid access in emerging markets, gradually building a sales network across multiple regions [4] Group 4: Shareholder Returns and Talent Incentives - The controlling shareholder, Dongbao Industrial Group, has increased its stake by 228 million yuan, reflecting confidence in the company's future [5] - The company plans to repurchase shares worth 20 to 40 million yuan for employee stock ownership or equity incentives, aiming to align interests among shareholders, the company, and employees [6] Group 5: Value Reassessment - Experts believe that as the revenue share of insulin analogs continues to rise, Tonghua Dongbao's profit structure and growth quality are expected to improve further [7] - The company is constructing a new growth pattern through the volume increase of insulin analogs, gradual realization of innovative drugs, and accelerated internationalization [7]

生物经济（970038）指数十大成份股详情如下： 证券之星消息，1月26日，生物经济（970038）指数报收于2278.54点，涨0.57%，成交406.86亿元，换 手率3.97%。当日该指数成份股中，上涨的有27家，华兰疫苗以20.0%的涨幅领涨，下跌的有23家，美 好医疗以5.46%的跌幅领跌。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流入合计8.04亿元，游资资金净流入合 计8901.37万元，散户资金净流出合计8.93亿元。成份股资金流向详情见下表： ...

凯普生物20cm涨停，智飞生物、万孚生物涨超10%，之江生物、华兰疫苗此前涨停，康希诺、硕世生 物、科华生物涨幅居前。 (本文来自第一财经) ...

医药股，集体异动！ 今日（1月26日）午后，医药股大幅走强，生物疫苗、体外诊断、肝炎等方向领涨。其中，凯普生物直线拉升 至20%涨停，用时不足1分钟；海王生物、科华生物等股票也陆续涨停。 印度突然出现尼帕病毒疫情，截至目前，印度已有5例确诊病例，其中包括医护人员。这一消息可能刺激了医 药股的上涨。另外，年初多个创新药BD交易落地，中国创新药出海趋势向好。有券商研究机构表示，随着更 多国产创新药的出海、医保谈判的常态化以及产业链的成熟，创新药赛道有望持续成为资金配置的核心方向。 医药股异动 午后，医药股突然拉升，凯普生物直线涨停，海王生物、科华生物、迈克生物、金迪克等股票也陆续封死涨停 板。此前，华兰疫苗、鲁抗医药、达安基因等个股已涨停。截至下午收盘，生物疫苗、流感指数涨幅超过 3%，体外诊断、肝炎指数涨超2%。 | (分时 1分钟 更多) | | 壳价 叠加 重播 统计 | 画线 F10 标记 -自选 返回 | | 凯普生物 300639 R | | 医疗保健 | | --- | --- | --- | --- | --- | --- | --- | --- | | 7.25 | 凯普生物 分时 成交量 | ...

Core Viewpoint - Microchip Biotech (688321.SH) is expected to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the same period last year, thus turning a profit [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, representing a year-on-year increase of about 168.03 million yuan, indicating a turnaround from loss to profit [1] - The company's revenue is expected to grow significantly, driven by the sales of its product, Siglecatin Sodium, which has seen a year-on-year increase of around 123% due to its unique clinical value and effective commercialization strategies [1] Group 2: Product Development and Market Recognition - The product, Sidabamine, has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025 [1] - The inclusion of Sidabamine in the latest version of the National Medical Insurance Directory under regular Class B management in December 2025 is expected to contribute to a year-on-year revenue growth of approximately 16% [1]

瑞财经 刘治颖 1月23日，盛禾生物-B(02898)公告，执行董事姜晓玲已获委任为公司首席执行官兼首席 科学官，自2026年1月23日起生效。 资料显示，姜晓玲，自2020年2月起加入集团，担任盛禾（中国）生物制药的副总经理及研发负责人。 她于2023年7月21日获委任为董事并于2023年7月22日获调任为执行董事且进一步获委任为副总裁，负责 管理研发部及产品注册。姜晓玲现时亦为盛禾（中国）生物制药、盛禾医药科技及盛禾（浙江）生物制 药的监事。 自2007年12月至2009年10月，姜晓玲担任宝船生物医药科技（上海）有限公司的研究员，参与蛋白表达 相关药物与细胞系构建工作。自2009年10月至2011年10月，她曾任南京金斯瑞生物科技有限公司高级研 究员，主要负责生产稳定的细胞系构建及生物彷制药研发。自2011年10月至2020年2月，她担任南京优 科制药有限公司项目负责人兼项目经理，主要负责化学药品研发。 姜晓玲于2005年7月取得位于山东省的山东农业大学生物技术学士学位，并于2008年6月进一步取得位于 江苏省的南京大学生物化学与分子生物学硕士学位。自2011年7月起，她获南京市称工作领导小组认证 为工 ...